Compare MYSZ & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | CDT |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | Israel | United States |
| Employees | 13 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.0M |
| IPO Year | N/A | N/A |
| Metric | MYSZ | CDT |
|---|---|---|
| Price | $0.53 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 91.8K | ★ 1.2M |
| Earning Date | 03-26-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,512,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $36.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.91 |
| 52 Week High | $3.04 | $225.60 |
| Indicator | MYSZ | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 29.59 | 40.41 |
| Support Level | $0.50 | $0.99 |
| Resistance Level | $0.67 | $1.18 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 17.04 | 37.95 |
My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.